Displaying 199 (all) recruiting clinical trials.
-
The AIM-HN and SEQ-HN Study: A 2 Cohort Non-comparative Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
The purpose of this research study is to see how effective the study drug is to treat your tumor. Other reasons for conducting the study ...Phase N/A
Interventional
-
A Phase II Study of High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of this study is to determine the rate of graft-versus-host disease (GvHD) for patients receiving bortezomib, known commercially as Velcade®, and cyclophosphamide, known ...Phase
Interventional
-
A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer (SGN22E-002)
The purpose of this study to find out how enfortumab vedotin, when given together with pembrolizumab, cisplatin, carboplatin, or gemcitabine, affects patients with metastatic urothelial ...Phase
Interventional
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
Interventional
-
The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
You are being asked to take part in this study because you have recurrent, platinum-resistant ovarian cancer. This means your ovarian cancer has grown or ...Phase
Interventional
-
A PHASE II RANDOMIZED CONTROLLED TRIAL OF NIVOLUMAB IN COMBINATION WITH BMS-986253 OR CABIRALIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS
The purpose of this research study is to determine whether treatment with Cabiralizumab or HuMax-IL8 in combination with Nivolumab has additional benefit to Nivolumab treatment ...Phase
Interventional
-
A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you ...Phase
Interventional
-
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
The main purpose of this study is to test the safety, tolerability, and effectiveness of the study drug tocilizumab when given with the drugs ipilimumab ...Phase
Interventional
-
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ...Phase
Interventional
-
A Multicenter Open label Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (MK3475-587)
The purpose of this extension study is to continue to collect long term information on the safety of the study drug, pembrolizumab or pembrolizumab-based combinations ...Phase
Interventional
